Receptor-targeted nanocarriers for therapeutic delivery to cancer
Open accessThe DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Abstract
Efficient and site-specific delivery of therapeutic drugs is a critical challenge in clinical treatment of cancer. Nano-sized carriers such as liposomes, micelles, and polymeric nanoparticles have been investigated for improving bioavailability and pharmacokinetic properties of therapeutics via various mechanisms, for example, the enhanced permeability and retention (EPR) effect. Further improvement can potentially be achieved by conjugation of targeting ligands onto nanocarriers to achieve selective delivery to the tumour cell or the tumour vasculature. Indeed, receptor-targeted nanocarrier delivery has been shown to improve therapeutic responses both in vitro and in vivo. A variety of ligands have been investigated including folate, transferrin, antibodies, peptides and aptamers. Multiple functionalities can be incorporated into the design of nanoparticles, e.g., to enable imaging and triggered intracellular drug release. In this review, we mainly focus on recent advances on the development of targeted nanocarriers and will introduce novel concepts such as multi-targeting and multi-functional nanoparticles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552 · cited 4×
“…capable of carrying large amount of drugs, having prolonged circulation time (especially when surface PEGylated), and facilitating selective tumour accumulation via the enhanced permeability and retention (EPR) effect (Jain 1999, Allen and Cullis 2004, Alexis et al. 2008, Soussan et al. 2009).”
InfluentialNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“To date, a variety of nanocarriers (e.g., liposomes, micelles, and polymeric nanoparitcles) have demonstrated efficacy both in vitro and in vivo (Allen and Cullis 2004, Duncan 2006, Peer et al. 2007, Davis et al. 2008, Jagur-Grodzinski 2009).”
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“However, in some cases, a non-internalizing antibody that only binds on cell surfacemay have the benefit of promoting greater bystander effects and enabling immunological mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC) (Clynes et al. 2000).”
BackgroundRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
A review of stimuli-responsive nanocarriers for drug and gene delivery
Ganta, S., Devalapally, H., Shahiwala, A., & Amiji, M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.017 · Cited by 2,155
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging
Veiseh, O., Gunn, J. W., & Zhang, M. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.002 · Cited by 1,832
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
The emerging nanomedicine landscape
Wagner, V., Dullaart, A., Bock, A.-K., & Zweck, A. (2006) · Nature Biotechnology · doi:10.1038/nbt1006-1211 · Cited by 1,630
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Pharmacokinetics and Biodistribution of Nanoparticles
Li, S.-D., & Huang, L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800049w · Cited by 1,568
Multidrug-resistance efflux pumps ? not just for resistance
Piddock, L. J. V. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1464 · Cited by 1,522
Nanomedicine—Challenge and Perspectives
Riehemann, K., Schneider, S. W., Luger, T. A., Godin, B., Ferrari, M., & Fuchs, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802585 · Cited by 1,305
TORCHILIN, V (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.009 · Cited by 1,273
Low, P. S., Henne, W. A., & Doorneweerd, D. D. (2008) · Accounts of Chemical Research · doi:10.1021/ar7000815 · Cited by 1,173
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
Dendrimer biocompatibility and toxicity
DUNCAN, R., & IZZO, L. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.019 · Cited by 1,158
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., & Ruoslahti, E. (2010) · Science · doi:10.1126/science.1183057 · Cited by 1,075
Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway
Qian, Z. M., Li, H., Sun, H., & Ho, K. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.561 · Cited by 1,019
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates
Caliceti, P. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00108-x · Cited by 947
Multifunctional magnetic nanoparticles for targeted imaging and therapy
MCCARTHY, J., & WEISSLEDER, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.014 · Cited by 892 · cited 3×
“MNPs have been combined with several anticancer drugs, including paclitaxel, doxorubicin, and methotrexate (MTX) (McCarthy and Weissleder 2008, Dilnawaz et al. 2010).”
Bhirde, A. A., Patel, V., Gavard, J., Zhang, G., Sousa, A. A., Masedunskas, A., Leapman, R. D., Weigert, R., Gutkind, J. S., & Rusling, J. F. (2009) · ACS Nano · doi:10.1021/nn800551s · Cited by 853
Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging
Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., & Li, K. C. P. (1998) · Nature Medicine · doi:10.1038/nm0598-623 · Cited by 850
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Targeting of drugs and nanoparticles to tumors
Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200910104 · Cited by 829
Multifunctional Gold Nanoparticle−Peptide Complexes for Nuclear Targeting
Tkachenko, A. G., Xie, H., Coleman, D., Glomm, W., Ryan, J., Anderson, M. F., Franzen, S., & Feldheim, D. L. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0296935 · Cited by 794
Protein nanoparticles as drug carriers in clinical medicine
Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.044 · Cited by 779
Mishra, B., Patel, B. B., & Tiwari, S. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.04.008 · Cited by 771
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Targeted pharmaceutical nanocarriers for cancer therapy and imaging
Torchilin, V. P. (2007) · The AAPS Journal · doi:10.1208/aapsj0902015 · Cited by 762
Aptamers Generated from Cell-SELEX for Molecular Medicine: A Chemical Biology Approach
Fang, X., & Tan, W. (2010) · Accounts of Chemical Research · doi:10.1021/ar900101s · Cited by 747
Specialization of tumour vasculature
Ruoslahti, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc724 · Cited by 722
Subcellular targeting strategies for drug design and delivery
Rajendran, L., Knölker, H.-J., & Simons, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2897 · Cited by 708
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695 · cited 1×
“For example, Abraxane, an albumin-nanoparticle formulation of paclitaxel, was approved by FDA in 2005 for the treatment of metastatic breast cancer (Dranitsaris et al. 2009, Miele et al. 2009).”
Transport of Molecules, Particles, and Cells in Solid Tumors
Jain, R. K. (1999) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.1.1.241 · Cited by 691
Tat peptide-mediated cellular delivery: back to basics
BROOKS, H., LEBLEU, B., & VIVES, E. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.001 · Cited by 667
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623 · cited 1×
“SP1049C, a micelle formulation of doxorubicin comprising pluronics, and NK911, another micelle formulation of doxorubicin comprising polyethylene glycol-poly (aspartic acid) block copolymer have been studied in clinical trials (Danson et al. 2004, Matsumura et al. 2004).”
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
Torchilin, V. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.026 · Cited by 583
RECENT APPROACHES TO INTRACELLULAR DELIVERY OF DRUGS AND DNA AND ORGANELLE TARGETING
Torchilin, V. P. (2006) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.8.061505.095735 · Cited by 543
Dendrimers: Emerging polymers for drug-delivery systems
Nanjwade, B. K., Bechra, H. M., Derkar, G. K., Manvi, F. V., & Nanjwade, V. K. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.07.008 · Cited by 542
Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs
Torchilin, V. P., Lukyanov, A. N., Gao, Z., & Papahadjopoulos-Sternberg, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931428100 · Cited by 538
The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells
Daniels, T. R., Delgado, T., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.006 · Cited by 518
Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery
Gullotti, E., & Yeo, Y. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900090z · Cited by 473
Polymeric micelles for drug delivery
Aliabadi, H. M., & Lavasanifar, A. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.1.139 · Cited by 446
Cell-penetrating and cell-targeting peptides in drug delivery
Vivès, E., Schmidt, J., & Pèlegrin, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.03.001 · Cited by 441
Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W.-L., Carter, P., Benz, C. C., & Papahadjopoulos, D. (1997) · Biochemistry · doi:10.1021/bi962148u · Cited by 439
Ligand-targeted liposomal anticancer drugs
Sapra, P., & Allen, T. M. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00032-8 · Cited by 438
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435
Drug Delivery by Soft Matter: Matrix and Vesicular Carriers
Soussan, E., Cassel, S., Blanzat, M., & Rico‐Lattes, I. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802453 · Cited by 433
Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells
Huang, Y., Shangguan, D., Liu, H., Phillips, J. A., Zhang, X., Chen, Y., & Tan, W. (2009) · ChemBioChem · doi:10.1002/cbic.200800805 · Cited by 422
Targeted Nanoparticles for Cancer Therapy
Reddy, G. S. N. (2021) · Journal of Bioanalysis & Biomedicine · Cited by 401
Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy
Dilnawaz, F., Singh, A., Mohanty, C., & Sahoo, S. K. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.057 · Cited by 385
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382 · cited 1×
“SP1049C, a micelle formulation of doxorubicin comprising pluronics, and NK911, another micelle formulation of doxorubicin comprising polyethylene glycol-poly (aspartic acid) block copolymer have been studied in clinical trials (Danson et al. 2004, Matsumura et al. 2004).”
Efficient Cancer Therapy with a Nanobody-Based Conjugate
Cortez-Retamozo, V., Backmann, N., Senter, P. D., Wernery, U., De Baetselier, P., Muyldermans, S., & Revets, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3935 · Cited by 382
Current methods for attaching targeting ligands to liposomes and nanoparticles
Nobs, L., Buchegger, F., Gurny, R., & Allémann, E. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20098 · Cited by 379
Targeted drug delivery via folate receptors
Zhao, X., Li, H., & Lee, R. J. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.3.309 · Cited by 358
Self-citationHeath, J. R., & Davis, M. E. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.061506.185523 · Cited by 354
Yang, J., Lee, C., Ko, H., Suh, J., Yoon, H., Lee, K., Huh, Y., & Haam, S. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200703554 · Cited by 331
Targeting Mitochondria with Organelle‐Specific Compounds: Strategies and Applications
Yousif, L. F., Stewart, K. M., & Kelley, S. O. (2009) · ChemBioChem · doi:10.1002/cbic.200900185 · Cited by 330
Yamada, Y., Akita, H., Kamiya, H., Kogure, K., Yamamoto, T., Shinohara, Y., Yamashita, K., Kobayashi, H., Kikuchi, H., & Harashima, H. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.11.002 · Cited by 321
MacDiarmid, J. A., Mugridge, N. B., Weiss, J. C., Phillips, L., Burn, A. L., Paulin, R. P., Haasdyk, J. E., Dickson, K.-A., Brahmbhatt, V. N., Pattison, S. T., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.012 · Cited by 307
In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
de Menezes, D. E. L., Pilarski, L. M., & Allen, T. M. (1998) · PubMed · Cited by 307
Patil, Y. B., Swaminathan, S. K., Sadhukha, T., Ma, L., & Panyam, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.048 · Cited by 304
Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy
Gindy, M. E., & Prud'homme, R. K. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902932908 · Cited by 298
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino, F., Brignole, C., Marimpietri, D., Cilli, M., Gambini, C., Ribatti, D., Longhi, R., Allen, T. M., Corti, A., & Ponzoni, M. (2003) · PubMed · Cited by 296
MacDiarmid, J. A., Amaro-Mugridge, N. B., Madrid-Weiss, J., Sedliarou, I., Wetzel, S., Kochar, K., Brahmbhatt, V. N., Phillips, L., Pattison, S. T., Petti, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1547 · Cited by 272
Nanotechnology and aptamers: applications in drug delivery
Levy-Nissenbaum, E., Radovic-Moreno, A. F., Wang, A. Z., Langer, R., & Farokhzad, O. C. (2008) · Trends in Biotechnology · doi:10.1016/j.tibtech.2008.04.006 · Cited by 270
Kakudo, T., Chaki, S., Futaki, S., Nakase, I., Akaji, K., Kawakami, T., Maruyama, K., Kamiya, H., & Harashima, H. (2004) · Biochemistry · doi:10.1021/bi035802w · Cited by 269
Yamada, Y., & Harashima, H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.016 · Cited by 259
Development of HPMA copolymer–anticancer conjugates: Clinical experience and lessons learnt
Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.007 · Cited by 252
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
Sharkey, R. M., & Goldenberg, D. M. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.4.226 · Cited by 242
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains
Silverman, J., Lu, Q., Bakker, A., To, W., Duguay, A., Alba, B. M., Smith, R., Rivas, A., Li, P., Le, H., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1166 · Cited by 237
Boddapati, S. V., D’Souza, G. G. M., Erdogan, S., Torchilin, V. P., & Weissig, V. (2008) · Nano Letters · doi:10.1021/nl801908y · Cited by 234
Peer, D., & Margalit, R. (2004) · International Journal of Cancer · doi:10.1002/ijc.11615 · Cited by 229
A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers
Saul, J. M., Annapragada, A. V., & Bellamkonda, R. V. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.028 · Cited by 227
Chemical approaches to the discovery and development of cancer therapies
Neidle, S., & Thurston, D. E. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1587 · Cited by 224
Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy
Misra, R., & Sahoo, S. K. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.11.010 · Cited by 219
Yaseen, A. D. B., Kawaguchi, T., & Jankowiak, R. (2009) · International Journal of Nanomanufacturing · doi:10.1504/ijnm.2009.028116 · Cited by 218
Redox-Triggered Contents Release from Liposomes
Ong, W., Yang, Y., Cruciano, A. C., & McCarley, R. L. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8050469 · Cited by 214
Peer, D., & Margalit, R. (2004) · Neoplasia · doi:10.1593/neo.03460 · Cited by 214
Phage display systems and their applications
Paschke, M. (2006) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-0270-9 · Cited by 208
DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells
D’Souza, G. G. M., Rammohan, R., Cheng, S.-M., Torchilin, V. P., & Weissig, V. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00297-9 · Cited by 203
DQAsomes: A Novel Potential Drug and Gene Delivery System Made from Dequalinium™
Weissig, V., Lasch, J., Erdos, G., Meyer, H. W., Rowe, T. C., & Hughes, J. (1998) · Pharmaceutical Research · doi:10.1023/a:1011991307631 · Cited by 193
Targeting hepatocytes for drug and gene delivery emerging novel approaches and applications
Wu, J. (2002) · Frontiers in Bioscience · doi:10.2741/a806 · Cited by 190
Doxorubicin‐Conjugated Immuno‐Nanoparticles for Intracellular Anticancer Drug Delivery
Shi, M., Ho, K., Keating, A., & Shoichet, M. S. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200801271 · Cited by 186
Lipid-Core Micelles for Targeted Drug Delivery
Torchilin, V. (2005) · Current Drug Delivery · doi:10.2174/156720105774370221 · Cited by 179
Colloidal soft matter as drug delivery system
Bonacucina, G., Cespi, M., Misici‐Falzi, M., & Palmieri, G. F. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21423 · Cited by 174
ElBayoumi, T. A., & Torchilin, V. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2392 · Cited by 170
LHRH-conjugated Magnetic Iron Oxide Nanoparticles for Detection of Breast Cancer Metastases
Leuschner, C., Kumar, C. S., Hansel, W., Soboyejo, W., Zhou, J., & Hormes, J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9199-7 · Cited by 165
Wagner, S., Rothweiler, F., Anhorn, M. G., Sauer, D., Riemann, I., Weiss, E. C., Katsen‐Globa, A., Michaelis, M., Cinatl, J. J., Schwartz, D., et al. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.093 · Cited by 162
Gosk, S., Vermehren, C., Storm, G., & Moos, T. (2004) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000135592.28823.47 · Cited by 160
Targeted Delivery Systems for Oligonucleotide Therapeutics
Yu, B., Zhao, X., Lee, L. J., & Lee, R. J. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9096-1 · Cited by 158
Self-citationBiomimetic Nanocarrier for Direct Cytosolic Drug Delivery
Zhang, Z., Cao, W., Jin, H., Lovell, J. F., Yang, M., Ding, L., Chen, J., Corbin, I., Luo, Q., & Zheng, G. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200903112 · Cited by 158
Development of ligand-targeted liposomes for cancer therapy
Noble, C. O., Kirpotin, D. B., Hayes, M. E., Mamot, C., Hong, K., Park, J. W., Benz, C. C., Marks, J. D., & Drummond, D. C. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.4.335 · Cited by 157
Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome
Negussie, A. H., Miller, J. L., Reddy, G., Drake, S. K., Wood, B. J., & Dreher, M. R. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.12.031 · Cited by 156
HDL‐Mimicking Peptide–Lipid Nanoparticles with Improved Tumor Targeting
Zhang, Z., Chen, J., Ding, L., Jin, H., Lovell, J. F., Corbin, I. R., Cao, W., Lo, P., Yang, M., Tsao, M., et al. (2009) · Small · doi:10.1002/smll.200901515 · Cited by 147
Kluza, E., van der Schaft, D. W. J., Hautvast, P. A. I., Mulder, W. J. M., Mayo, K. H., Griffioen, A. W., Strijkers, G. J., & Nicolay, K. (2010) · Nano Letters · doi:10.1021/nl902659g · Cited by 146
Chang, D.-K., Lin, C., Wu, C., & Wu, H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004171 · Cited by 142
Templated Spherical High Density Lipoprotein Nanoparticles
Thaxton, C. S., Daniel, W. L., Giljohann, D. A., Thomas, A. D., & Mirkin, C. A. (2009) · Journal of the American Chemical Society · doi:10.1021/ja808856z · Cited by 122
Park, K. M., Suh, K., Jung, H., Lee, D., Ahn, Y., Kim, J., Baek, K., & Kim, K. (2008) · Chemical Communications · doi:10.1039/b815009e · Cited by 121
Liposomes targeted via two different antibodies: Assay, B-cell binding and cytotoxicity
Laginha, K. M., Mumbengegwi, D. R., & Allen, T. M. (2005) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.02.007 · Cited by 119
Nikanjam, M., Blakely, E. A., Bjornstad, K. A., Shu, X., Budinger, T. F., & Forte, T. M. (2006) · eScholarship (California Digital Library) · Cited by 118
Lapalombella, R., Yu, B., Triantafillou, G., Liu, Q., Butchar, J. P., Lozanski, G., Ramanunni, A., Smith, L. L., Blum, W. G., Andritsos, L. A., et al. (2008) · Blood · doi:10.1182/blood-2008-01-133108 · Cited by 117
Self-citationOrganic nanoscale drug carriers coupled with ligands for targeted drug delivery in cancer
Shi, M., Lu, J., & Shoichet, M. S. (2009) · Journal of Materials Chemistry · doi:10.1039/b822319j · Cited by 101
Nanodiamonds as vehicles for systemic and localized drug delivery
Lam, R. T.-T., & Ho, D. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903156382 · Cited by 93
Multivalent RGD synthetic peptides as potent α V β 3 integrin ligands
Garanger, É., Boturyn, D., Coll, J., Favrot, M., & Dumy, P. (2006) · Organic & Biomolecular Chemistry · doi:10.1039/b517706e · Cited by 89
Aptamers and aptamer targeted delivery
Yan, A. C., & Levy, M. (2009) · RNA Biology · doi:10.4161/rna.6.3.8808 · Cited by 85
Voinea, M., Mânduțeanu, I., Butoi, E. D., Capraru, M., & Simionescu, M. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-7247-3 · Cited by 76
Toma, A., Otsuji, E., Kuriu, Y., Okamoto, K., Ichikawa, D., Hagiwara, A., Ito, H., Nishimura, T., & Yamagishi, H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602668 · Cited by 75
Futaki, S., Masui, Y., Nakase, I., Sugiura, Y., Nakamura, T., Kogure, K., & Harashima, H. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.796 · Cited by 73
Use of antibodies and immunoconjugates for the therapy of more accessible cancers
Sharkey, R. M., & Goldenberg, D. M. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.011 · Cited by 71
Polymers for targeted and/or sustained drug delivery
Jagur‐Grodzinski, J. (2008) · Polymers for Advanced Technologies · doi:10.1002/pat.1304 · Cited by 68
An Efficient Targeted Drug Delivery through Apotransferrin Loaded Nanoparticles
Krishna, A. D. S., Mandraju, R. K., Golla, K., & Kondapi, A. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007240 · Cited by 63
Delivery of drugs and macromolecules to mitochondria☆
Mukhopadhyay, A., & Weiner, H. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.004 · Cited by 61
A new human antitumor immunoreagent specific for ErbB2.
Lorenzo, C. D., Palmer, D. B., Piccoli, R., Ritter, M. A., & D’Alessio, G. (2002) · PubMed · Cited by 57
A novel DDS strategy, “dual-targeting”, and its application for antineovascular therapy
Murase, Y., Asai, T., Katanasaka, Y., Sugiyama, T., Shimizu, K., Maeda, N., & Oku, N. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.06.008 · Cited by 55
Laginha, K. M., Moase, E. H., Yu, N. Y., Huang, A., & Allen, T. M. (2008) · Journal of drug targeting · doi:10.1080/10611860802229978 · Cited by 53
Beuttler, J., Rothdiener, M., Müller, D., Frejd, F. Y., & Kontermann, R. E. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900061v · Cited by 53
Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv
Loomis, K. H., Smith, B. J., Feng, Y., Garg, H., Yavlovich, A., Campbell-Massa, R., Dimitrov, D. S., Blumenthal, R. P., Xiao, X., & Puri, A. (2010) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2010.01.006 · Cited by 47
Balestrieri, M. L., & Claudio Napoli, A. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.02.006 · Cited by 43
MacDiarmid, J. A., Madrid-Weiss, J., Amaro-Mugridge, N. B., Phillips, L., & Brahmbhatt, H. N. (2007) · Cell Cycle · doi:10.4161/cc.6.17.4648 · Cited by 39
Recent advances in tumor vasculature targeting using liposomal drug delivery systems
Lila, A. S. A., Ishida, T., & Kiwada, H. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903289928 · Cited by 38
Benedetto, M. D., Starzec, A. B., Vassy, R., Perret, G. Y., & Crépin, M. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.01.015 · Cited by 17
Cited by
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine
Sousa de Almeida, M., Susnik, E., Drasler, B., Taladriz-Blanco, P., Petri-Fink, A., & Rothen-Rutishauser, B. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01127d · Cited by 1,079
Innovative approaches for cancer treatment: current perspectives and new challenges
Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 814
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Metadata
- Authors
- Yu, B., Tai, H. C., Xue, W., Lee, L. J., & Lee, R. J.
- Venue
- Molecular Membrane Biology
- Publisher
- Informa UK Limited
- Published
- 2010-10
- Volume
- 27
- Issue
- 7
- Pages
- 286-298
- ISSN
- 0968-7688 (ISSN-L)
- 1464-5203
- OpenAlex
- W2165732324
- Cited by
- 423
- References
- 134
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.